Osteoporosis in men
Osteoporosis in men
复制标题
DOI：
10.1016/j.rce.2009.11.023
复制
发表时间：
2010-07-01
影响因子：
2.9
通讯作者：
Blazquez Cabrera, J. A.
中科院分区：
文献类型：
--
作者：
Moro-Alvarez, M. J.;Blazquez Cabrera, J. A.
男性骨质疏松症仍未得到充分诊断和治疗。它的存在使得有必要排除易感条件和疾病。应推荐一般预防措施，必要时还应补充1200毫克/天的钙和至少800国际单位/天的维生素d。双膦酸盐，特别是阿仑膦酸盐（ALN）和利塞膦酸盐（RSN），是治疗男性骨质疏松症的首选。在骨折高风险的严重病例和双膦酸盐治疗失败或不能耐受这些药物的患者中，可能建议使用特立帕肽。现有证据表明，ALN、RSN和特立帕肽治疗的抗骨折疗效在两性中是相似的。只有在临床上出现性腺功能减退的情况下，才需要雄激素。即使在这种情况下，如果骨折的风险很高，尽管雄激素替代，双膦酸盐或特立帕肽也可能与之相关。(C) 2009 Elsevier Espana， S.L.版权所有
Osteoporosis in men continues to be underdiagnosed and undertreated. Its presence makes it necessary to rule out predisposing conditions and diseases. General prevention measures should be recommended and when necessary also supplementation with 1200 mg/day of calcium and at least 800 IU/day of vitamin D. Bisphosphonates, specifically alendronate (ALN) and risedronate (RSN), are the treatment of choice in men with osteoporosis. In severe cases with high risk of fracture and in patients with therapeutic failure with the bisphosphonates or who do not tolerate these drugs, the use of teriparatide may be recommended. The evidence available suggests that anti-fracture efficacy of treatment with ALN, RSN and teriparatide is similar in both genders. Androgens are only justified if there is clinical hypogonadism. Even in this case, bisphosphonates or teriparatide should probably be associated if the risk of fracture is very high in spite of androgen replacement. (C) 2009 Elsevier Espana, S.L. All rights reserved.